Andrew Marr, John Kiser and Wim Cypers assess the current status and challenges of implementing of XEVMPD

Andrew Marr, John Kiser (AbbVie and Co-chair of the Article 57(2) Implementation Working Group) and Wim Cypers (ArisGlobal) assess the status of the implementation of XEVMPD, as of July 2013, and the challenges in moving forward towards improved quality and the maintenance cycle.

Click here to view the journal article.

This article was published in the October 2013 issue of Regulatory Rapporteur